A niosome formulation modulates the Th1/Th2 bias immune response in mice and also provides protection against anthrax spore challenge
Open Access
- 1 November 2018
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 7427-7440
Abstract
Introduction: In this study, we have investigated the immunogenicity and protective efficacy of a niosomal formulation encapsulating protective antigen (PA) and PA domain 4 (D4) of Bacillus anthracis. Methods: Nonionic surfactant–based vesicles (NISV) + PA and NISV + D4 were prepared from span-60 and cholesterol by reverse-phase evaporation method and were evaluated for in vitro characteristics and immunological studies. Results: Particle characterization using transmission electron microscopy and atomic force microscopy analysis showed that the niosomal formulation was spherical in shape. The entrapment efficiency values were calculated to be 58.5% and 44.75% for PA and D4, respectively. Confocal microscopy and flow cytometry studies showed an enhanced uptake of antigen in THP1 macrophages by niosome as compared to antigen only. An in vitro release assay showed a burst release of antigen from niosome within 24 hours followed by a gradual release for 144 hours. Immunological studies showed that both PA- and D4-encapsulated niosome elicited a robust IgG titer. Antibody isotyping and cytokine profile showed that NISV + PA and NISV + D4 enhanced both Th1 and Th2 responses in mice, suggesting a mixed Th1/Th2 response. Both NISV + PA and NISV + D4 elicited high levels of anti-inflammatory cytokine interleukin-10 with low levels of pro-inflammatory cytokine tumor necrosis factor-α, suggesting the anti-inflammatory property of niosome. Both the niosomal formulations were also able to confer protection against BA infection as compared to only PA and D4. Conclusion: PA and D4 encapsulated NISV formulation could modulate both the Th1 and Th2 adaptive immune system and was found to be a better prophylactic against anthrax.Keywords
This publication has 43 references indexed in Scilit:
- A Single-Dose PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation Protects Mice against Bacillus anthracis Spore ChallengePLOS ONE, 2013
- Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancementVirology Journal, 2012
- The early humoral immune response toBacillus anthracistoxins in patients infected with cutaneous anthraxFEMS Immunology & Medical Microbiology, 2011
- Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entitiesProceedings of the National Academy of Sciences, 2010
- The Protective Antigen Component of Anthrax Toxin Forms Functional Octameric ComplexesJournal of Molecular Biology, 2009
- A Viral Nanoparticle with Dual Function as an Anthrax Antitoxin and VaccinePLOS Pathogens, 2007
- Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects againstBacillus anthracisSpore ChallengeInfection and Immunity, 2007
- PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in miceInternational Journal of Pharmaceutics, 2007
- Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathwayJournal of Cell Biology, 2004
- Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured MacrophagesBiochemical and Biophysical Research Communications, 1998